Ovarian Germ Cell Tumor
9
3
6
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors